Key facts
- Coen Biotech’s last known valuation is $63.8M (Mar 2021).
- Notable investors include Tailong VC, Chengdu Bio-Town Investment, Hangzhou Tigermed Consulting Company, Kanghua Biology.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Coen Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Coen Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Coen Biotech
Developer of biotechnology applications designed for research and clinical purposes. The company offers molecular analysis tools, laboratory testing systems, and data integration functions with features such as sample processing, genetic information interpretation, quality control mechanisms, and compatibility with research workflows, enabling scientific institutions and healthcare providers to advance experimental studies, improve diagnostic processes, ensure reliable outcomes, and support innovation in biomedical applications.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2018
- Employees
- 37
- Website
- coenbiotech.com/
- Ownership
- Privately Held (backing)
Coen Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Coen Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Coen Biotech in its N-PORT filings yet. We sweep new filings monthly.